Explore the core pathogenesis of gastric "inflammation-cancer" transformation based on cag pathogenic island
-
摘要: 幽门螺杆菌(Helicobacter pylori，HP)是目前已知的诱发胃癌的首要可控危险因素。cag致病岛作为Ⅰ型HP强致病力产毒菌株的特殊生理学标志，具有编码致病菌中毒素、黏附因子、侵袭因子或其他毒力因子基因的作用，与HP对胃上皮细胞的毒力损害和致癌机制有直接关系。结合现代医学cag致病岛诱导胃“炎-癌”转化机制与中医学理论研究，认为胃“炎-癌”转化的中医核心病机为“脾虚湿困，毒损络阻”。本文通过探讨cag致病岛及其相关毒力因子的致炎致癌机制，阐释胃“炎-癌”转化的中医核心病机及诊治规律，以求探索有益于延缓、逆转胃“炎-癌”转化级联过程的中西医结合诊疗思路。Abstract: Helicobacter pylori(HP) is a well-established controllable risk factor for gastric cancer. The HP pathogenic island serves as a distinctive physiological marker for type ⅠHP strains that are strong producers of pathogenic viruses. It contains genes encoding toxins, adhesion factors, invasion factors, and other virulence factors, which are directly linked to the pathogenic damage and carcinogenic mechanisms of HP on epithelial cells. This paper integrates modern medical research on the "inflammation-cancer" transformation mechanism in the stomach with the theoretical study of Traditional Chinese Medicine(TCM). It posits that the core pathogenesis of TCM in gastric "inflammation-cancer" transformation is characterized by "spleen deficiency, dampness and turbidity, and toxic damage with collateral obstruction". The paper discusses the carcinogenic mechanisms of the cag pathogenic island and its associated virulence factors, elucidates the core pathogenesis of TCM, and outlines the diagnostic and treatment principles for gastric "inflammation-cancer" transformation. The aim is to explore diagnostic and treatment concepts that combine TCM with Western medicine, which could be beneficial in delaying and reversing the cascade process of gastric "inflammation-cancer" transformation.
-
-
[1] Li Q. Bacterial infection and microbiota in carcinogenesis and tumor development[J]. Front Cell Infect Microbiol, 2023, 13: 1294082. doi: 10.3389/fcimb.2023.1294082
[2] Zhang S, Shen Y, Liu H, et al. Inflammatory microenvironment in gastric premalignant lesions: implication and application[J]. Front Immunol, 2023, 14: 1297101. doi: 10.3389/fimmu.2023.1297101
[3] Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention[J]. Cancer Res, 1992, 52(24): 6735-6740.
[4] 唐旭东, 张泰, 卞立群, 等. 萎缩性胃炎与胃癌前病变诊疗研究的关键问题及其对策[J]. 中国中西医结合消化杂志, 2023, 31(5): 317-322. doi: 10.3969/j.issn.1671-038X.2023.05.01
[5] 王萍, 李鹏, 陈萦晅, 等. 中国整合胃癌前病变临床管理指南[J]. 胃肠病学, 2021, 26(2): 91-111. doi: 10.3969/j.issn.1008-7125.2021.02.005
[6] 张希颜, 张忠绵, 叶王宇, 等. Hp既往感染胃癌前病变的证型判别分析[J]. 北京中医药, 2023, 42(7): 795-798. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO202307030.htm
[7] 赵化成, 洪焰, 曾福生, 等. 胃癌前病变中医证型与Hp感染、胃黏膜病理改变相关性研究[J]. 实用中西医结合临床, 2021, 21(15): 3-5. https://www.cnki.com.cn/Article/CJFDTOTAL-SZXL202115002.htm
[8] 张学智, 魏玮, 蓝宇. 成人幽门螺杆菌引起的胃炎中西医协作诊疗专家共识(2020, 北京)[J]. 中医杂志, 2020, 61(22): 2016-2024. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202022023.htm
[9] 唐旭东, 刘林, 王凤云, 等. 胃癌二级预防与中医药对策[J]. 中国科学: 生命科学, 2022, 52(6): 812-822. https://www.cnki.com.cn/Article/CJFDTOTAL-JCXK202206003.htm
[10] 姜天童, 王少丽, 刘震. 基于新型医疗设备应用于慢性萎缩性胃炎诊断的文献可视化分析[J]. 中国医疗设备, 2022, 37(11): 127-131, 155. doi: 10.3969/j.issn.1674-1633.2022.11.027
[11] 曹芝郡, 姜永珊, 李吉彦, 等. 胃癌前病变细胞模型的建立及其在中医药研究中的应用[J]. 中国中医基础医学杂志, 2023, 29(7): 1208-1212. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202307034.htm
[12] 康丽杰, 张楠, 王晓鸽, 等. 中药药对治疗胃癌前病变的研究进展[J]. 中华中医药学刊, 2023, 41(11): 169-174. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202311033.htm
[13] 卢雪凤, 黄红侠, 周权, 等. 中医药治疗胃黏膜肠上皮化生的研究进展[J]. 中国中医基础医学杂志, 2023, 29(12): 2123-2127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202312037.htm
[14] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet, 1984, 1(8390): 1311-1315.
[15] Censini S, Lange C, Xiang ZY, et al. Cag a pathogenicity island of Helicobacte phlori: encode type Ⅰ-specific and disease-associated virulence factor[J]. Proc Natl Acad Sci USA, 1996, 93(25): 14646-14653.
[16] Reyes VE. Helicobacter pylori and Its Role in Gastric Cancer[J]. Microorganisms, 2023, 11(5): 1312. doi: 10.3390/microorganisms11051312
[17] Ahmadzadeh A, Rashidi M, Mohsenifar Z, et al. Helicobacter pylori Examining the effect of cagPAI variety on gene expression pattern related to gastric cancer[J]. Horm Mol Biol Clin Investig, 2023, 44(3): 251-258. doi: 10.1515/hmbci-2022-0048
[18] Canzian F, Rizzato C, Stein A, et al. Phylogenetic origin of Helicobacter pylori pathogenicity island and risk of stomach cancer and high-grade premalignant gastric lesions[J]. Eur J Cancer Prev, 2023, 32(3): 301-304. doi: 10.1097/CEJ.0000000000000779
[19] Azizimoghaddam Y, Kermanpour S, Mirzaei N, et al. Genetic diversity of Helicobacter pylori type Ⅳ secretion system cagI and cagN genes and their association with clinical diseases[J]. Sci Rep, 2023, 13(1): 10264. doi: 10.1038/s41598-023-37392-7
[20] Kang DM, Khalil AAK, Park WS, et al. Helicobacter pyloriAnti-Activity of Six Major Compounds Isolated from[J]. ACS Omega, 2023, 8(45): 42548-42554. doi: 10.1021/acsomega.3c05282
[21] Skakic I, Francis JE, Dekiwadia C, et al. Helicobacter pyloriAn Evaluation of Urease A Subunit Nanocapsules as a Vaccine in a Mouse Model of Infection[J]. Vaccines(Basel), 2023, 11(11): 1652.
[22] Johnston L, Guy-Von S, Zavan L, et al. The effect of altered pH growth conditions on the production, composition, and proteomes of Helicobacter pylori outer membrane vesicles[J]. Proteomics, 2023: e2300269.
[23] Yunle K, Tong W, Jiyang L, et al. Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review[J]. Helicobacter, 2024, 29(1): e13034. doi: 10.1111/hel.13034
[24] Valdez-Salazar HA, Ares MA, Fernández FJ, et al. Helicobacter pylori Long-chain fatty acids alter transcription of virulence and regulatory genes[J]. Peer J, 2021, 9: e12270. doi: 10.7717/peerj.12270
[25] Chattopadhyay I, Gundamaraju R, Rajeev A. Diversification and deleterious role of microbiome in gastric cancer[J]. Cancer Rep(Hoboken), 2023, 6(11): e1878.
[26] Varshney N, Kashyap D, Behra SK, et al. Predictive profiling of gram-negative antibiotics in CagA oncoprotein inactivation: a molecular dynamics simulation approach[J]. SAR QSAR Environ Res, 2023, 34(6): 501-521. doi: 10.1080/1062936X.2023.2230876
[27] Kashyap D, Koirala S, Roy R, et al. Computational insights into VacA toxin inhibition: harnessing FDA-approved antibiotics against Helicobacter pylori[J]. J Biomol Struct Dyn, 2023: 1-13.
[28] Saxena K, Kumar A, Chauhan N, et al. Electrochemical Immunosensor for Detection of H. pylori Secretory Protein VacA on g-C3N4/ZnO Nanocomposite-Modified Au Electrode[J]. ACS Omega, 2022, 7(36): 32292-32301. doi: 10.1021/acsomega.2c03627
[29] Kaneko K, Zaitoun M, Letley P, et al. The active form of Helicobacter pylori vacuolating cytotoxin induces decay-accelerating factor CD55 in association with intestinal metaplasia in the human gastric mucosa[J]. J Pathol, 2022, 258(2): 199-209. doi: 10.1002/path.5990
[30] Fu HW, Lai YC. The Role of Helicobacter pylori Neutrophil-Activating Protein in the Pathogenesis of H. pylori and Beyond: From a Virulence Factor to Therapeutic Targets and Therapeutic Agents[J]. Int J Mol Sci, 2022, 24(1): 91. doi: 10.3390/ijms24010091
[31] Wen SH, Hong ZW, Chen CC, et al. Helicobacter pylori Neutrophil-Activating Protein Directly Interacts with and Activates Toll-like Receptor 2 to Induce the Secretion of Interleukin-8 from Neutrophils and ATRA-Induced Differentiated HL-60 Cells[J]. Int J Mol Sci, 2021, 22(21): 11560. doi: 10.3390/ijms222111560
[32] Bravo J, Díaz P, Corvalán AH, et al. Helicobacter pylori A Novel Role for Gamma-Glutamyl transpeptidase in Regulating Autophagy and Bacterial Internalization in Human Gastric Cells[J]. Cancers(Basel), 2019, 11(6): 801.
[33] Liu K, Wang H, Zhou J, et al. HMGB1 in exosomes derived from gastric cancer cells induces M2-like macrophage polarization by inhibiting the NF-κB signaling pathway[J]. Cell Biol Int, 2024, 48(3): 334-346. doi: 10.1002/cbin.12110
[34] Hofmann R, Bäck M. Helicobacter pylori Time for Routine Screening in Coronary Artery Disease[J]. Circulation, 2023, 147(23): 1731-1733. doi: 10.1161/CIRCULATIONAHA.123.064944
[35] 张泰, 张北华, 马祥雪, 等. 慢性萎缩性胃炎炎-癌转化中医病机探析[J]. 中华中医药杂志, 2022, 37(11): 6414-6417. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202211040.htm
[36] 代倩兰, 刘慧敏, 刘绍能, 等. 基于扎根理论探究姚乃礼教授诊治慢性萎缩性胃炎的特点[J]. 中国中西医结合杂志, 2023, 43(11): 1380-1383. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202311015.htm
[37] 王丽, 张润顺, 包一珺, 等. 姚乃礼教授辨治脾胃病的经验浅析[J]. 时珍国医国药, 2022, 33(6): 1436-1438. doi: 10.3969/j.issn.1008-0805.2022.06.49
[38] 王少丽, 田志华, 姜天童, 等. 健脾祛湿解毒通络方联合补救四联疗法治疗难治性幽门螺杆菌感染的临床疗效观察[J]. 中国中西医结合消化杂志, 2024, 32 (4): 309-314. doi: 10.3969/j.issn.1671-038X.2024.04.08
[39] 赵智强. 周仲瑛教授对消化道恶性肿瘤的辨治研究[J]. 南京中医药大学学报, 2016, 32(1): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY201601001.htm
[40] 张潇潇, 刘浩, 朱广辉, 等. 肿瘤脾虚湿浊病机探讨及康莱特注射液作用特点[J]. 山东中医药大学学报, 2021, 45(4): 449-453. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYX202104006.htm
[41] 孙哲拯, 张培彤. "毒证"证候与"癌毒"病机的概念辨析[J]. 北京中医药大学学报, 2023, 46(9): 1237-1241. doi: 10.3969/j.issn.1006-2157.2023.09.008
[42] 马海刚, 高宏, 王晓东. 活血化瘀药治疗恶性肿瘤伴高凝状态的用药规律及安全性研究[J]. 中国处方药, 2023, 21(10): 138-141. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202310042.htm
[43] 陈纯辉, 孙学刚, 魏素芬, 等. 肿瘤微环境血瘀病机探讨[J]. 中西医结合研究, 2023, 15(3): 195-197, 201. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYH202303012.htm
[44] 熊潭玮, 江伟, 范剑薇. 中医药治疗胃癌前病变研究进展[J]. 中医学报, 2018, 33(6): 971-974. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK201806013.htm
[45] 刘震, 田志华, 王少丽, 等. 中医药治疗幽门螺杆菌感染的现状与展望[J]. 中国中西医结合消化杂志, 2024, 32(4): 283-287. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2024.04.03
[46] 徐晓惠. 连朴饮加味方干预Hp相关性萎缩性胃炎模型大鼠的疗效与作用机制研究[D]. 武汉: 湖北中医药大学, 2022.
[47] 钟成侃. 除幽方治疗耐药性幽门螺旋杆菌感染的临床观察及机制初探[D]. 杭州: 浙江中医药大学, 2022.
[48] 王敏. 基于microRNA-204-5p及TLR4/NF-kB信号通路探讨灭幽汤对HP相关性胃炎脾胃湿热证小鼠胃黏膜上皮细胞的影响[D]. 长沙: 湖南中医药大学, 2023.
[49] 刘婉琼. 基于HSP70/NF-κB通路健脾清化汤治疗Hp相关性胃炎大鼠的机制研究[D]. 北京: 北京中医药大学, 2020.
[50] 李一桐. 健脾清化化瘀汤对HP相关PLGC大鼠胃黏膜miR-21及其靶基因PTEN表达的影响[D]. 北京: 北京中医药大学, 2021.
[51] 陈末. 灭幽汤对HP相关性胃炎脾胃湿热证模型小鼠凋亡因子P27、Fasl、Bim的影响[D]. 长沙: 湖南中医药大学, 2019.
[52] 曾蓉. 灭幽汤对HP相关性胃炎脾胃湿热证模型小鼠PTEN-PI3K-Akt-FoxO凋亡信号通路的影响[D]. 长沙: 湖南中医药大学, 2019.
[53] 何晓曼, 王玉刚. 胃内非Hp菌群与胃癌和癌前状态演进的研究进展[J]. 胃肠病学, 2020, 25(9): 568-571. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC202009011.htm
-
下载:
计量
- 文章访问数: 393
- 施引文献: 0